Obesity, a pandemic of the modern world, is intimately associated with dyslipidemia, which
is mainly driven by the effects of insulin resistance and pro-inflammatory adipokines …

It is now about 20 years since the first case of a gain-of-function mutation involving the as-yet-
unknown actor in cholesterol homeostasis, proprotein convertase subtilisin/kexin type 9 …

Unknown 15 years ago, PCSK9 (proprotein convertase subtilisin/kexin type 9) is now
common parlance among scientists and clinicians interested in prevention and treatment of …

PCSK9 is an established target for cholesterol-lowering therapies. Further study of PCSK9
regulatory mechanisms may identify additional control points for pharmacological inhibition …

Objectives: The purpose of this study was assess the effect of evolocumab (AMG 145) on
lipoprotein (Lp)(a) from a pooled analysis of 4 phase II trials. Background: Lp (a), a low …

Obesity and its associated disorders, such as insulin resistance, dyslipidemia, metabolic
inflammation, dysbiosis, and non-alcoholic hepatic steatosis, are involved in several …

Proprotein convertase subtilisin/kexin type 9 (PCSK9), mainly synthetized and released by
the liver, represents one of the key regulators of low-density lipoprotein cholesterol …

Background: Alirocumab, a monoclonal antibody to proprotein convertase subtilisin/kexin
type 9 (PCSK9), lowers plasma low-density lipoprotein (LDL) cholesterol and apolipoprotein …

Lipoprotein (a)(Lp (a)) is a low-density lipoprotein (LDL) cholesterol-like particle bound to
apolipoprotein (a). Increased Lp (a) levels are an independent, heritable causal risk factor …

Lipoprotein (a)[Lp (a)] is independently associated with CVD risk. Evolocumab, a
monoclonal antibody (mAb) to proprotein convertase subtilisin/kexin type 9 (PCSK9) …